The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease

References

• Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998;101:1899–1904
   PubMed Web of Science ®Google Scholar
• Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998;91:4216–4223
   PubMed Web of Science ®Google Scholar
• Mohan JS, Lip GY, Wright J, Bareford D, Blann AD. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: Relationship to genotype and to inflammation. Blood Coagul Fibrinolysis 2005;16:209–214
   PubMed Web of Science ®Google Scholar
• Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: Potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006;26:1626–1631
   PubMed Web of Science ®Google Scholar
• Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001;137:398–407
   PubMed Web of Science ®Google Scholar
• Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Zuckerman L, Schlegel R, Williamson P. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 1999;134:352–362
   PubMed Web of Science ®Google Scholar
• Charneski L, Congdon HB. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature. Am J Health Syst Pharm 2010;67:895–900
   PubMedGoogle Scholar
• Serjeant GR. Sickle-cell disease. Lancet 1997;350:725–730
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021–1030
   PubMed Web of Science ®Google Scholar
• Inwald DP, Kirkham FJ, Peters MJ, Lane R, Wade A, Evans JP, Klein NJ. Platelet and leucocyte activation in childhood sickle cell disease: Association with nocturnal hypoxaemia. Br J Haematol 2000;111:474–481
   PubMed Web of Science ®Google Scholar
• Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: A curious paradox. Am J Med 2003;115:721–728
   PubMed Web of Science ®Google Scholar
• Beurling-Harbury C, Schade SG. Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol 1989;31:237–241
   PubMed Web of Science ®Google Scholar
• Francis RB Jr. Platelets, coagulation, and fibrinolysis in sickle cell disease: Their possible role in vascular occlusion. Blood Coagul Fibrinolysis 1991;2:341–353
   PubMed Web of Science ®Google Scholar
• Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007;139:3–13
   PubMed Web of Science ®Google Scholar
• Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost 1984;51:303–306
   PubMed Web of Science ®Google Scholar
• Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 1984;15:199–212
   PubMedGoogle Scholar
• Jakubowski JA, Winters KJ, Naganuma H, Walletin L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25:358–374
   Google Scholar
• Small DS, Li YG, Ernest CS 2nd, April JH, Farid NA, Payne CD, Winters KJ, Rohatagi S, Ni L. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel: A new thienopyridine antiplatelet agent. J Clin Pharmacol 2011;51:321–332
   PubMedGoogle Scholar
• Jakubowski JA, Li YG, Small DS, Payne CD, Tomlin ME, Juo J, Winters KJ. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol 2010;56:29--37
   Google Scholar
• Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL 3rd, Howard J, Mant TG, Jurcevic S, Payne CD. A phase 1 study of prasugrel in patients with sickle cell disease: Pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol 2013;75:1433–1444
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL 3rd, Gupta N, Howard J, Payne CD, Mant TG. A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation. Thromb Res 2014;133:190–195
   PubMed Web of Science ®Google Scholar
• Berny-Lang M, Frelinger AL 3rd, Barnard MR, Michelson AD. Flow cytometry. In: Michelson AD, ed. Platelets. 3rd ed. San Diego: Academic Press; 2013:581–602
   Google Scholar
• Barnard MR, Linden MD, Frelinger AL 3rd, Li Y, Fox ML, Furman MI, Michelson AD. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005;3:2563–2570
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi, A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007;98:192–200
   PubMed Web of Science ®Google Scholar
• Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL 3rd, Michelson AD. Leukocyte–platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 2001;142:790–798
   PubMedGoogle Scholar
• Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008;6:359–365
   PubMed Web of Science ®Google Scholar
• Braun OO, Johnell M, Varenhorst C, James S, Brandt JT, Jakubowski JA, Winters KJ, Wallentin L, Erlinge D, Siegbahn A. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008;100:626–633
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet Activation and Inhibition in Sickle cell disease (PAINS) study. Platelets 2014;25:27–35
   PubMed Web of Science ®Google Scholar
• Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 1997;129(5):507–516
   PubMed Web of Science ®Google Scholar